• Worst Pills, Best Pills



• Health Letter



• Health Links



• Activist Courses



• Take Action!



• Drug Safety



• Healthcare Delivery



• Medical Devices



• Food Safety



• Occupational Health

Publications:

» (1/29/09) Testimony of Sidney Wolfe Before Food and Drug Administration Advisory Committee on Propoxyphene (DARVON) (HRG Publication #1856) » (7/31/07) Testimony Before the Senate Judiciary Committee on Oxycontin and the Prosecution of Purdue (HRG Publication #1821) » (4/12/07) Testimony before the FDA Arthritis Advisory Committee concerning Arcoxia (HRG Publication #1806) » (2/28/06) Petition to FDA to ban all propoxyphene (DARVON) products; prescription painkiller causes many fatalities (HRG Publication #1762) » (4/7/05) Bextra Ban a Good Step, But FDA Should Pull Celebrex Too (HRG Publication #1734) » (2/28/05) Painkillers and Terrorism. Letter to the Editor of the New York Times on Cox 2 Painkillers (HRG Publication #1727) » (2/17/05) Testimony to FDA on Dangers of Cox-2 Drugs (HRG Publication #1725) » (1/31/05) Letter to FDA revealing heart dangers in an unpublished clinical trial of Celebrex (HRG Publication #1721) » (1/24/05) Petition to remove the Cox-2 Inhibitors Celecoxib (CELEBREX) and Valdecoxib (BEXTRA) From the Market (HRG Publication #1720) » (12/23/04) Response to FDA's Announcement about Use of Celebrex and Bextra (HRG Publication #1714) » (9/30/04) Vioxx, Other “Super Aspirins” Are Super Disasters – Other Cox-2 Alternatives Have Safety Problems Too (HRG Publication #1707) » (10/15/02) Letter to FDA addressing Dr. Gary Firestein's comments concerning HRG's petition to remove ARAVA from the market (HRG Publication #1644) » (9/19/02) Statement on Safety Issues Related to Acetaminophen Before the Nonprescription Drugs Advisory Committee (HRG Publication #1639) » (4/1/02) Petition to ban arthritis drug leflunomide (ARAVA) (HRG Publication #1614) » (1/7/01) Testimony before the FDA Arthritis Drugs Advisory Committee on the Nonsteroidal Anti-Inflammatory Drugs Celecoxib and Rofecoxib (HRG Publication #1555) » (12/1/98) Statement before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the nonsteroidal anti-inflammatory drug celecoxib. (HRG Publication #1465) » (8/11/97) Comments supporting the Drug Enforcement Administration's proposed placement of butorphanol (Stadol and Stadol Nasal Spray) into Schedule IV. (HRG Publication #1422) » (10/11/95) Testimony of Sidney M. Wolfe, MD, Before the FDA Arthritis Advisory Committee on the Petition to Ban Piroxicam (Feldene) (HRG Publication #1373)

more resources

Because Public Citizen does not accept funds from corporations, professional associations or government agencies, we can remain independent and follow the truth wherever it may lead. But that means we depend on the generosity of concerned citizens like you for the resources to fight on behalf of the public interest. If you would like to help us in our fight, click here.